Innovative Medicine Backed by the Power of Artificial Intelligence

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology.

About Us

Company’s Approach to Drug Development

Company’s Approach to Drug Development

AI-based Drug Development

Our neuroscience and immuno-oncology programs utilize our approach to drug development.

BXCL501

BXCL501 is an investigational sublingual thin film formulation of dexmedetomidine in development for acute treatment of agitation in multiple neuropsychiatric indications.

BXCL701

BXCL701 is an investigational orally-available systemic innate immunity activator in development for the treatment of a rare form of prostate cancer and for the treatment of pancreatic cancer.

Latest News

BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML)

View Release

BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501

View Release

BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update

View Release
View all news

Sign up for Email Alerts

Email Sign Up

Stock Information

BioXcel Therapeutics, Inc.

View Investor Relations View Investor Presentation